Publications by authors named "S Hietanen"
Article Synopsis
- The management of advanced ovarian cancer (AOC) has improved due to molecular diagnostics that help predict how patients will respond to PARP inhibitors, particularly based on homologous recombination deficiency (HRD) status.
- This study analyzed tumor samples from a clinical trial to investigate why HRD status isn't always a reliable indicator of sensitivity to PARP inhibitors.
- Key findings included that some HRD-negative samples showed responses to treatment despite their status, while some HRD-positive samples did not, emphasizing the need to consider other genetic factors beyond HRD status.
Background: As the treatment landscape for advanced ovarian cancer (OC) evolves, it is important to understand patient outcomes in real-world clinical practice. OCRWE-Finland was an observational cohort study investigating OC outcomes, including treatment patterns, time to next treatment 1 (TTNT1), overall survival and healthcare resource utilisation, in Finland during the pre-PARPi era.
Materials And Methods: Patients included in OCRWE-Finland were diagnosed with OC between 2014 and 2019.
Background: Despite recent treatment advances in ovarian cancer (OC), more real-world evidence studies investigating patient outcomes are needed. OCRWE-Finland was an observational cohort study investigating OC outcomes in Finland during the pre-PARP inhibitor era.
Patients: Patients were diagnosed with OC between 2014 and 2019 in Finland.
Article Synopsis
- Mismatch repair-deficient (dMMR) endometrial cancer is associated with poor outcomes and limited treatment options, particularly for high-risk patients after surgery.
- In a phase III clinical trial, patients with dMMR tumors were treated with pembrolizumab plus chemotherapy, showing improved disease-free survival (DFS) rates compared to those who received placebo.
- The interim analysis revealed a significant DFS benefit for pembrolizumab, with a two-year DFS rate of 92.4% versus 80.2% for the placebo group, indicating its potential effectiveness in high-risk dMMR endometrial cancer.
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
Int J Gynecol Cancer
January 2025
Objective: In the ENGOT-EN6-NSGO/GOG3031/RUBY trial, dostarlimab+carboplatin-paclitaxel demonstrated significant improvement in progression free survival and a positive trend in overall survival compared with placebo+carboplatin-paclitaxel, with manageable toxicity, in patients with primary advanced or recurrent endometrial cancer. Here we report on patient-reported outcomes in the mismatch repair-deficient/microsatellite instability-high population, a secondary endpoint in the trial.
Methods: Patients were randomized 1:1 to dostarlimab+carboplatin-paclitaxel or placebo+carboplatin-paclitaxel every 3 weeks for 6 cycles followed by dostarlimab or placebo monotherapy every 6 weeks for ≤3 years or until disease progression.